Sunday, September 30, 2018

Dr Reddy#39;s Labs terminates Armis Biopharma#39;s licence for its investigational antibacterial product

Dr Reddy#39;s Labs terminates Armis Biopharma#39;s licence for its investigational antibacterial product According to a press release issued by the Indian drug maker, as a result of the termination, Dr Reddy#39;s has regained worldwide rights to DFA-02, and is currently evaluating its options to take the programme forward.

from Moneycontrol Business News https://ift.tt/2Iutlyu
Labels:

No comments:

Post a Comment

Subscribe to: Post Comments (Atom)

IREDA shares rise 1.1% as board announces meeting date for fund raise via QIP

IREDA shares rose by 1.1% to Rs 209.50 on news of a board meeting set for January 23, 2025, to approve fund-raising via Qualified Institutio...